|
H · S · G Therapeutic Trials TETRA-HD: A Randomized, Double-Blind, Placebo-Controlled, Study of Tetrabenazine for the Treatment of Huntington’s Chorea ...Recruitment for TETRA-HD has been completed as of December 2003... Please see the February 2006 Press Release, at: www.huntington-study-group.org/TETRAHDFeb2006PressRelease.htm and the August 2003 Press Release at: www.huntington-study-group.org/TETRAHDPressRelease.htm The Huntington Study Group (HSG), under the direction of Frederick Marshall, MD (University of Rochester), has conducted a multi-center, double-blind, placebo-controlled study of tetrabenazine. TETRA-HD is designed to assess and gather information on the optimal dosage of tetrabenazine. The HSG has recruited more than 70 participants who are 18 years of age or older and who have chorea as a significant feature of their HD. For each patient the study will last approximately 15 weeks. At the end of the trial, patients will be offered the option to continue treatment for an additional 6 to 12 months. Please see the results of the TETRA-HD study at: www.huntington-study-group.org/HSGResearchNews.htm#TetraAbstract |
HDSA Center of Excellence at Hennepin County Medical Center